|IACP Partners with DQSA Coalition Members on Two Efforts|
IACP has signed onto two letters brought forth by our DQSA Coalition partners.
1. The first is a letter from the American Academy of Dermatology Association requesting a meeting with the FDA regarding the compounding of quinacrine. As you may remember, the Pharmacy Compounding Advisory Committee voted this spring to NOT put quinacrine on the positive list, removing a widely used treatment option for those suffering from Lupus. The letter is signed by the American Academy of Dermatology, American College of Rheumatology, Lupus & Allied Disease Association, Lupus Foundation of America, Lupus Research Alliance, NCPA, PCCA and IACP.
2. The second is a letter regarding, mainly, the naming and quality standards to be used for biologics and biosimilars. Currently, there is a bill in the Senate (SB 2700) called the “FDA and NIH Workforce Authorities Modernization Act” which would, among other things, exempt certain biologics and biosimilars from requiring to adhere to USP Standards. The letter was led by USP and signed on by the Academy of Managed Care Pharmacy, APhA, American Society of Consultant Pharmacists, ASHP, the Biosimilars Council, NASPA, NCPA, NCPDP and IACP. Press Release Here.
Tell us how compounded pharmaceuticals have helped you, someone you know, or how you have helped someone as a practicing compounding pharmacist. Help us protect your continued access to pharmacy compounding!
Share the P3 community and the value and necessity of personalized prescriptions with your friends.